Search
Research
COVID-19 vaccine coverage targets to inform reopening plans in a low incidence settingSince the emergence of SARS-CoV-2 in 2019 through to mid-2021, much of the Australian population lived in a COVID-19-free environment. This followed the broadly successful implementation of a strong suppression strategy, including international border closures. With the availability of COVID-19 vaccines in early 2021, the national government sought to transition from a state of minimal incidence and strong suppression activities to one of high vaccine coverage and reduced restrictions but with still-manageable transmission.
Research
Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trialThe use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and is recommended in many guidelines, but there is limited evidence underpinning this.
Research
Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on ImmunizationWHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available to all globally. To mark the 50-year anniversary of EPI, we sought to quantify the public health impact of vaccination globally since the programme's inception.
Research
Individual variation in vaccine immune response can produce bimodal distributions of protectionThe ability for vaccines to protect against infectious diseases varies among individuals, but computational models employed to inform policy typically do not account for this variation. Here we examine this issue: we implement a model of vaccine efficacy developed in the context of SARS-CoV-2 in order to evaluate the general implications of modelling correlates of protection on the individual level.
Research
Correlates of immunity to Group A Streptococcus: a pathway to vaccine developmentUnderstanding immunity in humans to Group A Streptococcus (Strep A) is critical for the development of successful vaccines to prevent the morbidity and mortality attributed to Strep A infections. Despite decades of effort, no licensed vaccine against Strep A exists and immune correlates of protection are lacking; a major impediment to vaccine development.
Research
Developmental outcomes following vaccine-proximate febrile seizures in childrenTo compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
News & Events
Researchers share their expertise with the community in CockburnResearchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.
Research
Comorbidities and confusion: addressing COVID-19 vaccine access and information challengesEarly in the coronavirus disease 2019 (COVID-19) pandemic, evidence emerged that individuals with chronic and immunocompromising conditions faced increased risk of severe infection, including death. The Australian Government and public health authorities prioritised these citizens' access to vaccines, including them in phase 1b of the rollout from 22 March 2021.
News & Events
Collaborating to prevent killer diseases in PNGFor more than a decade, The Kids Research Institute Australia and Papua New Guinea Institute of Medical Research have been fighting against killer infectious diseases.
Research
FluCAN - The Influenza Complications Alert NetworkThe main aim of the study is to provide timely surveillance data to public health authorities on severe influenza.